Skip to main content
Erschienen in: World Journal of Surgical Oncology 1/2012

Open Access 01.12.2012 | Case report

Invasive ductal breast cancer metastatic to the sigmoid colon

verfasst von: Xiao-cong Zhou, Hong Zhou, Ying-hai Ye, Xiu-feng Zhang, Yi Jiang

Erschienen in: World Journal of Surgical Oncology | Ausgabe 1/2012

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Abstract

The most common sites of breast cancer metastasis are the bone, lung, liver and brain. However, colonic metastases from breast cancer are very rare in the clinic. We describe an unusual case of sigmoid colonic metastasis from invasive ductal breast cancer. With this report, we should increase the clinical awareness that any patient with a colorectal lesion and a history of malignancy should be considered to have a metastasis until proven otherwise. Early diagnosis is very important, which enables prompt initiation of systemic treatment, such as chemotherapy, endocrine therapy or both, thus avoiding unnecessary radical surgical resection and improving the prognosis.
Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1477-7819-10-256) contains supplementary material, which is available to authorized users.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

XCZ performed the literature review, drafted and revised the manuscript. HZ, YHY and XFZ participated in the design of the study and revised the manuscript for intellectual content. YJ evaluated the histopathological features and contributed to the histopathological section of the manuscript. All authors read and approved the final manuscript.
Abkürzungen
CA
carbohydrate antigen
CDX2
cauda-related homeobox transcription factor 2
CEA
carcinoembryonic antigen
CK
cytokeratin
CT
computed tomography
ER
estrogen receptor
HER-2
human epidermal growth factor receptor-2
IHC
immunohistochemistry
PR
progesterone receptor
TTF-1
thyroid transcription factor-1.

Background

Metastatic involvement of the gastrointestinal tract secondary to breast cancer is rare[1] and sigmoid colonic metastasis from breast cancer is even rarer. Metastatic breast carcinoma involvement of the gastrointestinal tract is usually of the lobular histologic subtype[2]. To the best of our knowledge, the case presented here is one very rarely reported in literature, showing sigmoid colonic metastasis from invasive ductal breast cancer.

Case presentation

A 54-year-old woman was admitted to our hospital with pain in the left lower abdomen in April 2011. She had undergone modified radical mastectomy for an invasive ductal carcinoma of the right breast in December 2002. Histopathological examination revealed a 3.0 × 3.0 cm invasive ductal carcinoma of histological grade 3 and all seven resected axillary lymph nodes were negative for carcinoma. Immunohistochemistry (IHC) staining showed that the right breast cancer was positive for estrogen receptor (ER), progesterone receptor (PR) and p53, but negative for human epidermal growth factor receptor-2 (HER-2). The patient received adjuvant chemotherapy and endocrine therapy postoperatively. During a period of six years and one month, she was free of disease until January 2009, when she developed left breast carcinoma, for which she had undergone modified radical mastectomy. Histopathological examination revealed a 3.5 × 2.5 cm invasive ductal carcinoma of histological grade 3 and two of seventeen axillary lymph nodes were positive for carcinoma. IHC staining showed that the left breast cancer was positive for ER, PR and p53, but negative for HER-2. The patient received adjuvant chemotherapy, radiotherapy and endocrine therapy postoperatively. She had also undergone a total hysterectomy and bilateral salpingo-oophorectomy for left ovarian metastasis of breast carcinoma in November 2010, followed by second-line chemotherapy.
Physical examination revealed no palpable abdominal mass. Laboratory results showed mild anemia (hemoglobin level, 105 g/L), serum carbohydrate antigen (CA)125 level elevated to 134.4 kU/L (normal, 0 to about 35.0 kU/L), and serum CA724 level elevated to 139.8 kU/L (normal, 0 to about 6.9 kU/L), while serum levels of CA199, CA153, and carcinoembryonic antigen (CEA) were within the normal range. Endoscopy of the sigmoid showed mucosal irregular hyperplasia at 16 to about 30 cm above the anal verge, taking up about half of the intestinal lumen. The affected mucosal surface was eroded, necrotic, friable and prone to bleeding (Figure 1). Contrast-enhanced computed tomography (CT) showed eccentric wall thickening of the distal sigmoid colon with a significantly enhanced soft tissue density mass causing an apparent stenosis and nodular low density shadow in the left side (Figure 2). The sigmoid colonic biopsy specimen showed histological features of poorly differentiated adenocarcinoma (Figure 3) which was quite similar to that of the previous invasive ductal breast cancer (Figures 4 and5). IHC staining (Figure 6) showed that the sigmoid colon cancer was negative for (cauda-related homeobox transcription factor 2) CDX2, Villin, thyroid transcription factor-1 (TTF-1), cytokeratin (CK)20, HER-2, ER and PR, but positive for CK7 and p53. IHC staining also showed that the positive cell population of Ki-67 was 30%. The sigmoid colonic lesion was, therefore, diagnosed to be a metastasis from the original breast cancer.

Conclusions

The diagnosis was invasive ductal breast cancer metastatic to the sigmoid colon, which as a clinical entity can be easily misdiagnosed as primary sigmoid colon cancer. In the presented material, besides the medical history, a firm diagnosis of metastatic breast carcinoma to the sigmoid colon could be established fundamentally. It was based on the histology of the endoscopic biopsy specimen and immunohistochemistry. Metastatic breast carcinomas are often positive for CK7, ER and PR, but negative for CK20 and CDX2[2]. CK7 was positive but CK20 and CDX2 were negative in the present case, which was similar to reports in the literature. However, ER and PR were negative in the sigmoid colon site, which was different from a positive expression of the primary bilateral invasive ductal breast cancer (Table 1). The conversion from hormone receptor positive in the primary tumor to hormone receptor negative in the metastasis has also been reported in a series of studies[3, 4].
Table 1
Immunohistochemical markers for the primary bilateral invasive ductal breast cancer and metastases
 
The right breast cancer
The left breast cancer
The left ovarian metastasis
The sigmoid colonic metastasis
ER
15% estrogen receptor positive
20% estrogen receptor positive
20% estrogen receptor weak positive
0 estrogen receptor positive
PR
10% progesterone receptor positive
5% progesterone receptor positive
0 progesterone receptor positive
0 progesterone receptor positive
HER-2
negative
negative
negative
negative
p53
positive
positive
positive
positive
The diagnosis of colorectal metastasis is difficult not only because it is infrequent but also because of its non-specific clinical presentation and variable radiographic features[5]. So clinicians should increase their clinical awareness that any patient with a colorectal lesion and a history of malignancy should be considered to have a metastasis until proven otherwise. The therapeutic management of colorectal metastasis is still controversial. Surgical resection should be reserved for palliation of intestinal obstruction or bleeding[6]. Many authors underline the importance of early diagnosis, which enables prompt initiation of systemic treatment, such as chemotherapy, endocrine therapy or both, thus avoiding unnecessary radical surgical resection and improving the prognosis. Our patient underwent second-line chemotherapy and endocrine therapy after the diagnosis of sigmoid colonic metastasis from breast cancer. She is alive with disease and in stable condition at present.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

XCZ performed the literature review, drafted and revised the manuscript. HZ, YHY and XFZ participated in the design of the study and revised the manuscript for intellectual content. YJ evaluated the histopathological features and contributed to the histopathological section of the manuscript. All authors read and approved the final manuscript.
Literatur
1.
Zurück zum Zitat Bamias A, Baltayiannis G, Kamina S, Fatouros M, Lymperopoulos E, Agnanti N, Tsianos E, Pavlidis N: Rectal metastases from lobular carcinoma of the breast: report of a case and literature review. Ann Oncol. 2001, 12: 715-718. 10.1023/A:1011192827710.CrossRefPubMed Bamias A, Baltayiannis G, Kamina S, Fatouros M, Lymperopoulos E, Agnanti N, Tsianos E, Pavlidis N: Rectal metastases from lobular carcinoma of the breast: report of a case and literature review. Ann Oncol. 2001, 12: 715-718. 10.1023/A:1011192827710.CrossRefPubMed
2.
Zurück zum Zitat O’Connell FP, Wang HH, Odze RD: Utility of immunohistochemistry in distinguishing primary adenocarcinomas from metastatic breast carcinomas in the gastrointestinal tract. Arch Pathol Lab Med. 2005, 129: 338-347.PubMed O’Connell FP, Wang HH, Odze RD: Utility of immunohistochemistry in distinguishing primary adenocarcinomas from metastatic breast carcinomas in the gastrointestinal tract. Arch Pathol Lab Med. 2005, 129: 338-347.PubMed
3.
Zurück zum Zitat Hye Jung C, Sae-Won H, Do-Youn O, Seock-Ah I, Yoon Kyung J, In Ae P, Wonshick H, Dong-Young N, Yung-Jue B, Tae-You K: Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab. Jpn J Clin Oncol. 2011, 41: 593-599. 10.1093/jjco/hyr020.CrossRef Hye Jung C, Sae-Won H, Do-Youn O, Seock-Ah I, Yoon Kyung J, In Ae P, Wonshick H, Dong-Young N, Yung-Jue B, Tae-You K: Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab. Jpn J Clin Oncol. 2011, 41: 593-599. 10.1093/jjco/hyr020.CrossRef
4.
Zurück zum Zitat Arslan C, Sari E, Aksoy S, Altundag K: Variation in hormone receptor and HER-2 status between primary and metastatic breast cancer: review of the literature. Expert Opin Ther Targets. 2011, 15: 21-30. 10.1517/14656566.2011.537260.CrossRefPubMed Arslan C, Sari E, Aksoy S, Altundag K: Variation in hormone receptor and HER-2 status between primary and metastatic breast cancer: review of the literature. Expert Opin Ther Targets. 2011, 15: 21-30. 10.1517/14656566.2011.537260.CrossRefPubMed
5.
Zurück zum Zitat Taal BG, Den Hartog Jager FCA, Steinmetz R, Peterse H: The spectrum of gastrointestinal metastases of breast carcinoma: II. The colon and rectum. Gastrointest Endosc. 1992, 38: 136-141. 10.1016/S0016-5107(92)70378-2.CrossRefPubMed Taal BG, Den Hartog Jager FCA, Steinmetz R, Peterse H: The spectrum of gastrointestinal metastases of breast carcinoma: II. The colon and rectum. Gastrointest Endosc. 1992, 38: 136-141. 10.1016/S0016-5107(92)70378-2.CrossRefPubMed
6.
Zurück zum Zitat Schwarz RE, Klimstra DS, Turnbull AD: Metastatic breast cancer masquerading as gastrointestinal primary. Am J Gastroenterol. 1998, 93: 111-114. 10.1111/j.1572-0241.1998.111_c.x.CrossRefPubMed Schwarz RE, Klimstra DS, Turnbull AD: Metastatic breast cancer masquerading as gastrointestinal primary. Am J Gastroenterol. 1998, 93: 111-114. 10.1111/j.1572-0241.1998.111_c.x.CrossRefPubMed
Metadaten
Titel
Invasive ductal breast cancer metastatic to the sigmoid colon
verfasst von
Xiao-cong Zhou
Hong Zhou
Ying-hai Ye
Xiu-feng Zhang
Yi Jiang
Publikationsdatum
01.12.2012
Verlag
BioMed Central
Erschienen in
World Journal of Surgical Oncology / Ausgabe 1/2012
Elektronische ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-10-256

Weitere Artikel der Ausgabe 1/2012

World Journal of Surgical Oncology 1/2012 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.